Dra. Eva Gonzalez is PhD in Molecular Biology, is a Senior scientist and group leader of the Transformation and Metastasis laboratory, at the Spanish National Cancer Research Center (CNIO) in Madrid, Spain.
Her academic merits and research have been recognized with an ERC-Consolidator grant, ERC-Proof of Concept, a Susan Komen career catalyst grant, overlapping grants from multiple public and private agencies, and several awards. She is member of experts committee in several institutions as the Agencia Estatal de Investigación, European network of breast development and cancer (ENBDC), among others, and has supervised several PhD students and postdocs.
Research in her laboratory aims to identify novel targets for breast cancer treatment and understand mechanisms of resistance to current drugs. She has more than 50 publications, half of them in D1 and half as corresponding author.
To highlight a topic of her extensive research career, one of her main contributions of research has focused on the role of RANK in mammary epithelial homeostasis, breast cancer and tumor immunology, with studies from basic to clinical research. She coordinates a clinical trial in breast cancer patients.
Oncólogos médicos: Sonia Pernas, Catalina Falo, contrato indefinido Instituto Catalán de Oncología, Hospital de Bellvitge.
Adv Exp Med Biol. 2025;1464:309–345. doi: 10.1007/978-3-031-70875-6_16.
Breast Cancer Res. 2025;27:68. doi: 10.1186/s13058-025-01996-w.
G Perez-Chacon, P G Santamaria, J Redondo-Pedraza, E Gonzalez Suarez (AC). RANK/RANKL signaling pathway in Breast Development and Cancer. Adv Exp Med Biol 2025:1464:309-345. doi: 10.1007/978-3-031-70875-6_16.
I Gomes,(…) Gonzalez-Suarez, S Casimiro. RANK pathway inhibition sensitizes triple-negative breast cancer to CDK4/6 inhibitors and enhances immune response. Mol Cancer
Ther 2025. doi: 10.1158/1535-7163.MCT-24-1158.